世界のリアルワールドエビデンスソリューション市場 – 2030年までの業界動向と予測

 リアルワールドエビデンスソリューション市場の分析と規模

新製品の安全性と有効性に関する正確で透明な情報を得るための RWE ソリューションの需要が高まっています。さらに、複雑で併存疾患のある患者が使用した場合のさまざまな反応、製品のサブポピュレーション効果、製品価値を検出するこれらのソリューションの必要性が高まっています。これは、急成長するヘルスケア業界と相まって、市場の成長を促進しています。さらに、臨床開発、商品化、イノベーションの加速、ヘルスケアの成果の向上のために RWE で高度な分析と技術ソリューションの使用が増えていることも、市場にプラスの影響を及ぼしています。

Data Bridge Market Research の分析によると、リアルワールドエビデンスソリューション市場は 2022 年に 14 億 8,000 万米ドル規模で、2023 年から 2030 年の予測期間中に 14.4% の CAGR で成長し、2030 年には 43 億 3,000 万米ドルに達すると予想されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Research がまとめた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

リアルワールドエビデンスソリューション市場の範囲とセグメンテーション  

Market Definition

Real-world evidence (RWE) is organized information derived from clinical outcomes or judgments based on real-world data (RWD). RWD uses observational data to gain insights, extrapolate findings, and forecast diseases, medical devices, patient populations, and products. This is a data collection process used by the healthcare sector to make decisions. It gathers information from existing secondary sources, such as databases.

Real World Evidence Solutions Market Dynamics

Drivers

• Collaboration and innovations

An industry coalition to innovate and expand the use of RWE promotes market growth. For instance, in May 2021, five companies-Aetion, IQVIA, Flatiron Health, Tempus, and Syapse-joined forces to expand the use of data derived from EHRs, claims, and other sources beyond clinical trials. The coalition will also collaborate with pharmaceutical companies, medical device manufacturers, patient groups, and other key stakeholders to support broader efforts around using RWE, which members say helps developers, regulators, and providers better understand medical product safety and efficacy. These are the certain innovations which propel the growth of market.

• New product launches

In 2021, the International Society for Pharmacoeconomics and Outcomes Research, a US-based professional society for health economics and outcomes research, stated that the Real-World Evidence Transparency Initiative launched the Real-World Evidence Registry. By launching the RWE registry and establishing a culture of transparency for the analysis and reporting of RWE in healthcare and health research, the Real-World Evidence Transparency Initiative assists in addressing potential concerns with RWE studies.

Opportunities

• Reducing drug development costs and expediting the drug development process

The Tufts Center for the Study of Drug Development (CSDD) reported the median cost of bringing a new drug to market, which was significantly lower than previous research. According to the study's findings, a further USD 312 million is spent on post-approval development for a lifecycle, which includes tests of new indications, formulations, and dosage strengths. As the amount of RWD increases and its accessibility increases, companies will have the opportunity to use RWE earlier in the product lifecycle to help expedite development and reduce costs.

Restraints/Challenges

• Issues such as a reluctance

Issues such as a reluctance rely on real-world studies are expected to hamper the growth of the real world evidence solutions market. In the forecast period of 2023 to 2030, the real world evidence solutions market is expected to face challenges due to a lack of universally accepted methodological standards and data processing infrastructure.

This real world evidence solutions market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the real world evidence solutions market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Real World Evidence Solutions Market

Market participants also shifted their focus to providing solutions to stem the spread of the COVID-19 pandemic, which hampered market growth. The market is expected to recover post-COVID, with a 6.07% year-on-year growth rate from 2020 to 2021. Many companies began to deploy many remote services during the pandemic, which is expected to help these companies expand their portfolios.

Recent Developments

• In 2021, Syneos Health partnered with Aetion to provide a real-world evidence solution that includes analytical-driven data and regulatory-grade data.
• In 2022, Cegedim acquired Clinityx, a French medical data expert, strengthening its position in Real-World-Data.
• In 2022, Verantos, the global leader in high-validity real-world evidence (RWE), announced the launch of the Verantos Evidence Platform.

Global Real World Evidence Solutions Market Scope

The real world evidence solutions market is segmented on the basis of component, therapeutic area and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Component

• Data Sets
• Clinical Settings Data
• Claims Data
• Pharmacy Data
• Patient-powered Data
• Services

 Therapeutic Area

• Oncology
• Cardiovascular Disease
• Neurology
• Immunology
• Others Therapeutic Areas

 End User

• Pharmaceutical and Medical Device Companies
• Healthcare Payers
• Healthcare Providers
• Other End Users

Real World Evidence Solutions Market Regional Analysis/Insights

The real world evidence solutions market is analyzed and market size insights and trends are provided by country, component, therapeutic area and end user as referenced above.

The countries covered in the real world evidence solutions market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the real world evidence solutions market due to a favourable regulatory environment, a well-established pharmaceutical industry, high number of RWE service providers, demand in clinical research activities and increasing research and development expenditure in the region.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the growing incidence of cancer such as bladder, esophagus, liver, pancreas, and others, high presence of major manufacturers across the U.S. Furthermore, technological advancements and rising foreign investment.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The real world evidence solutions market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for real world evidence solutions market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the real world evidence solutions market. The data is available for historic period 2011-2021.

Competitive Landscape and Real World Evidence Solutions Market Share Analysis

リアルワールドエビデンスソリューション市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータポイントは、リアルワールドエビデンスソリューション市場に関連する会社の焦点にのみ関連しています。

リアルワールドエビデンスソリューション市場で活動している主要企業は次のとおりです。

• IBMコーポレーション（米国）
• IQVIA（米国）
• サーモフィッシャーサイエンティフィック株式会社（米国）
• パレクセルインターナショナルコーポレーション（米国）
• オプタム社（米国）
• パーキンエルマー社（米国）
• ICON plc（アイルランド）
• オラクル（米国）
• コグニザント（米国）
• サイネオス・ヘルス（米国）
• アンセム保険会社（米国）
• クリニゲン・リミテッド（英国）
• SAS Institute Inc.（米国）
• デロイト トウシュ トーマツ リミテッド（英国）
• クワンツィグ（インド）
• カーディナルヘルス（米国）
• アメリソースバーゲンコーポレーション（米国）

SKU-60273